Clinical trial

Cisplatin and Nab-paclitaxel for (N2) Defined NSCLC

NCT02276560

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2015-01-01

PhasePHASE2

Study timeline

Study start (unknown)2015-01-01Date precision: month

Registry last updated2017-05-11

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Stage IIIA Non-Small Cell Lung Cancerunresolved

Interventions

Neoadjuvant Cisplatin, nab-paclitaxelDRUG

Adjuvant Cisplatin,nab-paclitaxelDRUG

Adjuvant cisplatin+pemetrexed or cisplatin+gemcitabineDRUG

Sponsors & collaborators

UNC Lineberger Comprehensive Cancer Centerlead sponsor

Mapped research locations

AtlantaGeorgia, United States1 SeattleWashington, United States1 ClevelandOhio, United States1 PittsburghPennsylvania, United States1 TampaFlorida, United States1 Chapel HillNorth Carolina, United States1 New OrleansLouisiana, United States1 Kansas CityKansas, United States1 RaleighNorth Carolina, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02276560 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.